Skip to main content
. 2010 Jul 1;101(10):2220–2226. doi: 10.1111/j.1349-7006.2010.01662.x

Figure 3.

Figure 3

 Cells were treated with lapatinib (0.1, l μmol/L; A), bortezomib (1, 10 nmol/L; B) or lapatinib (0.1, l μmol/L) combined with bortezomib (1, 10 nmol/L) for 72 h. Western blot analysis was done for phosphorylated HER2 (p‐HER2) and total HER2, AKT and p‐AKT, ERK and p‐ERK, p‐4E‐BP1 and total P27. The GAPDH served as a loading control.